Journal of Medicinal Chemistry · 2010 · 28 citations · 19 references
MedicineMedicinal ChemistryPharmacologyBiochemical PharmacologyDrug DiscoveryMolecular PharmacologyEnzyme InhibitionMolecular Targets Of DrugsAromatic Nucleophilic SubstitutionChemical SubstituentsCytotoxicity AssaysEnzymatic InhibitionNicotinamide PhosphoribosyltransferaseNicotinic Acid Phosphoribosyltransferase
We have shown previously that the target of the potent cytotoxic agent 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB38065, 1) is nicotinamide phosphoribosyltransferase (Nampt). With its cellular target known we sought to optimize the biochemical and cellular Nampt activity of 1 as well as its cytotoxicity. It was found that a 3-pyridylmethylamide substituent in the A region was critical to cellular Nampt activity and cytotoxicity, although other aromatic substitution did yield compounds with submicromolar enzymatic inhibition. Small unsaturated groups worked best in the D-region of the molecule, with 3,3-dimethylallyl providing optimal potency. The E region required a quinazolin-4-one or 1,2,3-benzotriazin-4-one group for activity, and many substituents were tolerated at C² of the quinazolin-4-one. The best compounds showed subnanomolar inhibition of Nampt and low nanomolar cytotoxicity in cellular assays.
19
Efficient Access to Azaindoles and Indoles
Mark McLaughlin, Michael Palucki, Ian W. Davies · Organic Letters · 2006 · 127 citations
A Phase I study of CHS 828 in patients with solid tumor malignancy.
Peter Hovstadius, Rolf Larsson, Elin Jonsson et al. · PubMed · 2002 · 122 citations
Medicine, Oncology, Pharmacology +13